Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation - PubMed
11 hours ago
- #PD-L1
- #nanodrug
- #cancer immunotherapy
- Development of Cadict nanodrug to co-induce cuproptosis and disulfidptosis for enhancing PD-L1 checkpoint therapy.
- Cadict utilizes copper-sulfur coordination and glucose oxidase to create a hypoglycemic environment for disulfidptosis.
- Dual cytotoxic mechanism triggers immunogenic cell death and activates the integrated stress response (ISR), increasing PD-L1 expression.
- Synergy between redox-driven cytotoxicity and immune modulation enhances anti-PD-L1 efficacy, leading to tumor regression and immunological memory.
- Provides a new strategy to overcome ICB resistance by targeting tumor redox vulnerabilities.